Minerva Neurosciences announces two executive promotions
- BySeeking Alpha-
Minerva Neurosciences has appointed Geoff Race as president and Frederick Ahlholm as chief financial officer.
Minerva Neurosciences has appointed Geoff Race as president and Frederick Ahlholm as chief financial officer.
Minerva Neurosciences Inc (NASDAQ: NERV) announced results from a bioequivalence study comparing roluperidone formulations used in Phase 2b and Phase 3 trials and the planned...
WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 121.90 | 121.90 | 121.90 | +1.90 | +1.58% | 17.24K | London | |||
| 0.55 | 0.00 | 0.00 | +0.08 | +15.79% | 2.00M | Aquis Exchange | |||
| 326.00 | 326.50 | 324.00 | +1.50 | +0.46% | 565.22K | London | |||
| 75.00 | 75.00 | 64.50 | +11.50 | +18.11% | 109.81K | London | |||
| 1,399.60 | 1,405.00 | 1,389.80 | -2.20 | -0.16% | 7.81M | London | |||
| 1,043.00 | 1,050.50 | 1,033.00 | +4.50 | +0.43% | 2.60M | London | |||
| 315.00 | 322.00 | 312.00 | +9.00 | +2.97% | 279.56K | London | |||
| 2,599.00 | 2,618.50 | 2,595.50 | +6.0 | +0.23% | 2.50M | London | |||
| 189.25 | 190.05 | 181.05 | +7.25 | +3.98% | 18.40M | London | |||
| 110.44 | 111.28 | 109.64 | -0.68 | -0.61% | 59.55M | London | |||
| 2,456.00 | 2,499.00 | 2,444.00 | -5.00 | -0.20% | 147.56K | London | |||
| 434.20 | 436.05 | 430.70 | +8.20 | +1.93% | 36.06M | London | |||
| 2,604.00 | 2,681.00 | 2,601.00 | -71.0 | -2.65% | 1.15M | London | |||
| 644.20 | 652.40 | 633.20 | +13.60 | +2.16% | 4.33M | London | |||
| 5.49 | 5.50 | 5.49 | 0.00 | 0.00% | 0.00 | London |
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.